You are currently viewing Engineering Micelles for Antibody Capture

Engineering Micelles for Antibody Capture

Capture of antibodies in biopharmaceutical processes is most commonly performed using affinity chromatography on Protein A.  While Protein A works well, the commercially available chromatography resin is expensive and its use requires testing of the bulk drug substance for residual Protein A leached from the chromatography column during operation.  There has been interest for a long time in bulk phase methods, such as two-phase liquid extraction, as a lower cost alternative for antibody capture.  Now a new bulk phase extraction method that appears to offer high purity for immunoglobulins has been reported.

A group led by Guy Patchornik from Ariel University in Israel investigated the ability to use engineered micelles, or detergent aggregates, made of Tween 20, a hydrophobic metal chelator and Fe2+ ions, to efficiently capture immunoglobulins from cell culture medium. Their findings demonstrate the ability to purify human and mouse IgG antibodies with 70-80% yield from serum-free medium while preserving their secondary structure. This platform is an intriguing antibody purification strategy, and the authors suggest that it could potentially replace Protein A column purification. The article, “A general platform for antibody purification utilizing engineered-micelles,” is authored by Gunasekaran Dhandapani, Assaf Howard, Thien Van Truong, Thekke V. Baiju, Ellina Kesselman, Noga Friedman, Ellen Wachtel, Mordechai Sheves, Dganit Danino, Irishi N. N. Namboothiri & Guy Patchornik and appears in mAbs 2019, vol 11(3), 583-592.  DOI: 10.1080/19420862.2019.1565749.

Chamow & Associates assists biotechnology companies in producing novel therapies such as mAbs and engineered mAb derivatives for clinical testing.  We welcome your inquiry.